Liver cirrhosis in diabetes mellitus; a complication not always recognized;Levercirrose bij diabetes mellitus, een nietaltijd onderkende complicatie

Nederlands Tijdschrift voor Geneeskunde

Volumn 152, Issue 44, 2008, Pages 2369-2374

  Thewissen, C M I ^a   Tiebosch, A T M ^a   Kloppenburg, W D ^a   Haagsma, E B ^a   Hoogenberg, K ^a  

^a MARTINI HOSPITAL   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; ASCITES; CASE REPORT; CLINICAL FEATURE; DIABETES MELLITUS; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LIVER BIOPSY; LIVER CIRRHOSIS; MALE; NONALCOHOLIC FATTY LIVER; RISK FACTOR;

AGED; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; OBESITY; PREVALENCE; RISK FACTORS; RISK REDUCTION BEHAVIOR;

EID: 55849111930     PISSN: 00282162     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Rutten GEHM, Grauw WJC de, Nijpels G, Goudswaard AN, Uitewaal PJM, Does FEE van der, et al. NHG-standaard Diabetes mellitus type 2. Tweede herziening. Huisarts Wet. 2006;49:137-52.
2. Ballegooie E van, Everdingen JJ van. CBO-richtlijnen over diagnostiek, behandelingen prevenue van complicaties bij diabetes mellitus: retinopathie, voetulcera, nefropathie en hart- en vaatziekten. Ned Tijdschr Geneeskd. 2000;144:413-8.
3. Jansen PLM. Niet-alcoholische steatohepatitis: diagnostiek, pathogenese, behandelingen prognose. Ned Tijdschr Geneeskd. 2005;149:289-94.
4. Oldenburg B, Berge Henegouwen GP van. Beleid bij verhoogde serumwaarden van aminotransferasen zonder Symptomen, in het bijzonder bij non-alcoholische steatohepatitis. Ned Tijdschr Geneeskd. 1999;143:506-9.
5. Oldenburg B, Pijl H. Abdominale adipositas: metabole complicaties en gevolgen voor de lever. Ned Tijdschr Geneeskd. 2001;145:1290-4.
6. Farrell GC, Larter CZ. Nonalcoholic fatty liver disease: from steatosis to cirrhosis. Hepatology. 2006;43(2 Suppl 1):S99-112.
7. Marceau P, Biron S, Hould FS, Marceau S, Simard S, Thung SN, et al. Liver pathology and the metabolic syndrome X in severe obesity. J Clin Endocrinol Metab. 1999;84:1513-7.
8. DelGaudio A, Boschi L, DelGaudio GA, Mastrangel L, Munars D. Liver damage in obese persons. Obes Surg. 2001;11:254-7.
9. Targher G, Bertolini L, Rodella S, Tessari R, Zenari L, Lippi G, et al. Nonalcoholic fatty liver disease is independently associated with an increased incidence of cardiovascular events in type 2 diabetic patients. Diabetes Care. 2007;30:2119-21.
10. Bugianesi E, Leone N, Vanni E, Marchesini G, Brunello F, Carucci P, et al. Expanding the natural history of nonalcoholic steatohepatitis: from cryptogenic cirrhosis to hepatocellular carcinoma. Gastroenterology. 2002;123:134-40.
11. Matteoni CA, Younossi ZM, Gramlich T, Boparai N, Liu YC, McCullough AJ. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology. 1999;116:1413-9.
12. Lee RG. Nonalcoholic steatohepatitis: a study of 49 patients. Hum Pathol. 1989;20:594-8.
13. Adams LA, Sanderson S, Lindor KD, Angulo P. The histological course of nonalcoholic fatty liver disease: a longitudinal study of 103 patients with sequential liver biopsies. J Hepatol. 2005;42:132-8.
14. Powell EE, Cooksley WG, Hanson R, Searle J, Halliday JW, Powell LW. The natural history of nonalcoholic steatohepatitis: a follow-up study of forty-two patients for up to 21 years. Hepatology. 1990;11:74-80.
15. Bacon BR, Farahvash MJ, Janney CG, Neuschwander-Tetri BA. Nonalcoholic steatohepatitis: an expanded clinical entity. Gastroenterology. 1994;107:1103-9.
16. Ratziu V, Giral P, Charlotte F, Bruckert E, Thibault V, Theodorou I, et al. Liver fibrosis in overweight patients. Gastroenterology. 2000;118:1117-23.
17. Harrison SA, Torgerson S, Hayashi PH. The natural history of nonalcoholic fatty liver disease: a clinical histopathological study. Am J Gastroenterol. 2003;98:2042-7.
18. Browning JD, Szczepaniak LS, Dobbins R, Nuremberg P, Horton JD, Cohen JC, et al. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology. 2004;40:1387-95.
19. McCullough AJ. The epidemiology and risk factors of NASH. In: Farrell GC, George J, Hall P, McCullough AJ, editors. Fatty liver disease: NASH and related disorders. Maiden: Blackwell; 2005. p. 23-37.
20. Dekker JM, Kraan M van der, Nijpels G, Vegt F de, Kostense PJ, Stehouwer CD, et al. Schatting van het aantal nieuwe patiënten met diabetes mellitus type 2 in Nederland: ruim 65.000 per jaar in de leeftijdsgroep vanaf 50 jaar. Ned Tijdschr Geneeskd. 2003;147:1419-23.
21. Palekar NA, Naus R, Larson SP, Ward J, Harrison SA. Clinical model for distinguishing nonalcoholic steatohepatitis from simple steatosis in patients with nonalcoholic fatty liver disease. Liver Int. 2006;26:151-6.
22. Belfort R, Harrison SA, Brown K, Darland C, Finch J, Hardies J, et al. A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. N Engl J Med. 2006;355:2297-307.